Overview
The marketing authorisation for DepoCyte has been withdrawn at the request of the marketing authorisation holder.
DepoCyte : EPAR - Summary for the public
English (EN)
(507.77 KB - PDF)View
български (BG)
(661.62 KB - PDF)
español (ES)
(569.14 KB - PDF)
čeština (CS)
(632.39 KB - PDF)
dansk (DA)
(569.13 KB - PDF)
Deutsch (DE)
(714.1 KB - PDF)
eesti keel (ET)
(568.03 KB - PDF)
ελληνικά (EL)
(1.25 MB - PDF)
français (FR)
(569.55 KB - PDF)
italiano (IT)
(572.16 KB - PDF)
latviešu valoda (LV)
(637.75 KB - PDF)
lietuvių kalba (LT)
(593.61 KB - PDF)
magyar (HU)
(627.27 KB - PDF)
Malti (MT)
(571.84 KB - PDF)
Nederlands (NL)
(568.96 KB - PDF)
polski (PL)
(632.99 KB - PDF)
português (PT)
(570.42 KB - PDF)
română (RO)
(592.76 KB - PDF)
slovenčina (SK)
(630.99 KB - PDF)
slovenščina (SL)
(626.68 KB - PDF)
Suomi (FI)
(568.87 KB - PDF)
svenska (SV)
(568.38 KB - PDF)
Product information
DepoCyte : EPAR - Product Information
English (EN)
(755.24 KB - PDF)View
български (BG)
(1.36 MB - PDF)
español (ES)
(798.17 KB - PDF)
čeština (CS)
(1.18 MB - PDF)
dansk (DA)
(840.85 KB - PDF)
Deutsch (DE)
(1.1 MB - PDF)
eesti keel (ET)
(770.12 KB - PDF)
ελληνικά (EL)
(2.4 MB - PDF)
français (FR)
(786.49 KB - PDF)
hrvatski (HR)
(322.7 KB - PDF)
íslenska (IS)
(279.42 KB - PDF)
italiano (IT)
(780.81 KB - PDF)
latviešu valoda (LV)
(1.15 MB - PDF)
lietuvių kalba (LT)
(800.85 KB - PDF)
magyar (HU)
(1.14 MB - PDF)
Malti (MT)
(1.13 MB - PDF)
Nederlands (NL)
(776.99 KB - PDF)
norsk (NO)
(284.34 KB - PDF)
polski (PL)
(1.13 MB - PDF)
português (PT)
(778.53 KB - PDF)
română (RO)
(897.66 KB - PDF)
slovenčina (SK)
(1.11 MB - PDF)
Suomi (FI)
(771.39 KB - PDF)
svenska (SV)
(765.06 KB - PDF)
Latest procedure affecting product information: N/0059
26/06/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
DepoCyte : EPAR - All Authorised presentations
English (EN)
(505.86 KB - PDF)View
български (BG)
(538.83 KB - PDF)
español (ES)
(512.35 KB - PDF)
čeština (CS)
(531.7 KB - PDF)
dansk (DA)
(506.59 KB - PDF)
eesti keel (ET)
(496.5 KB - PDF)
ελληνικά (EL)
(520.27 KB - PDF)
français (FR)
(505.96 KB - PDF)
italiano (IT)
(502.84 KB - PDF)
latviešu valoda (LV)
(531.14 KB - PDF)
lietuvių kalba (LT)
(517.85 KB - PDF)
magyar (HU)
(522.39 KB - PDF)
Malti (MT)
(533.64 KB - PDF)
Nederlands (NL)
(505.52 KB - PDF)
polski (PL)
(531.52 KB - PDF)
português (PT)
(512.51 KB - PDF)
română (RO)
(518.92 KB - PDF)
slovenčina (SK)
(530.76 KB - PDF)
slovenščina (SL)
(520.2 KB - PDF)
Suomi (FI)
(502.61 KB - PDF)
svenska (SV)
(513.13 KB - PDF)
Product details
- Name of medicine
- DepoCyte
- Active substance
- cytarabine
- International non-proprietary name (INN) or common name
- cytarabine
- Therapeutic area (MeSH)
- Meningeal Neoplasms
- Anatomical therapeutic chemical (ATC) code
- L01BC01
Pharmacotherapeutic group
Antineoplastic agentsTherapeutic indication
Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.
Assessment history
DepoCyte : EPAR - Procedural steps taken and scientific information after authorisation
English (EN)
(591.51 KB - PDF)View
Topics
This page was last updated on